← Back to Search

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA)

DHA supplement for Inflammation

N/A
Waitlist Available
Led By Peter F Knickerbocker, DO
Research Sponsored by Walter Reed National Military Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during last month of pregnancy
Awards & highlights

Study Summary

This trial will study the effects of DHA supplementation during pregnancy on DHA levels, a novel anti-inflammatory metabolite, and inflammatory biomarkers.

Eligible Conditions
  • Inflammation
  • Pregnancy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during last month of pregnancy
This trial's timeline: 3 weeks for screening, Varies for treatment, and during last month of pregnancy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure DHA
Tumor Markers
Measure synaptamide
Secondary outcome measures
APGAR score at 1 min
APGAR score at 5 min
Culture proven sepsis
+39 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: DHA supplementActive Control1 Intervention
Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
Group II: corn oil: Soybean oil placeboPlacebo Group1 Intervention
Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.

Find a Location

Who is running the clinical trial?

Walter Reed National Military Medical CenterLead Sponsor
138 Previous Clinical Trials
33,804 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,705 Previous Clinical Trials
7,507,011 Total Patients Enrolled
32 Trials studying Inflammation
3,355 Patients Enrolled for Inflammation
DSM Nutritional Products, Inc.Industry Sponsor
93 Previous Clinical Trials
57,069 Total Patients Enrolled
2 Trials studying Inflammation
964 Patients Enrolled for Inflammation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies
2019. "Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04069195.
All > Sah
~34 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top